New Type 2 Diabetes And Obesity Treatment Approved – EndoBarrier Receives European CE Mark

GI Dynamics, a leader in non-surgical, endoscopic treatments for type 2 diabetes and obesity, today announced that it has received European CE mark approval for the EndoBarrier(TM), a non-surgical therapy to treat type 2 diabetes and obesity. The CE marking (an acronym for the French “Conformite Europeenne”) certifies that a product has met EU requirements for marketing in Europe. Clinical trials involving more than 270 patients have demonstrated the significant weight loss and diabetes improvement achieved with the EndoBarrier Gastrointestinal Liner…

Read more from the original source: 
New Type 2 Diabetes And Obesity Treatment Approved – EndoBarrier Receives European CE Mark

Related posts:

1. Gore Receives European CE Mark Approval For Next Generation Conformable GORE TAG(R) Thoracic Endoprosthesis W.L. Gore & Associates (Gore) announced that it has received European CE Mark approval for the next generation GORE TAG® Thoracic Endoprosthesis. ...
2. FDA Approved Drug May Slow Beta Cell Destruction In Type 1 Diabetes Patients New findings by UT Southwestern researchers suggest that a drug already used to treat autoimmune disorders might also help slow the destruction of insulin-producing cells in patients recently diagnosed with...
3. Type 2 Diabetes Gene Predisposes Children To Obesity Pediatric researchers have found that a gene already implicated in the development of type 2 diabetes in adults also raises the risk of being overweight during childhood. The finding sheds...
4. Echo Therapeutics Announces Positive Results Of A Clinical Study Testing Symphony(TM) TCGM System In Patients With Type 1 And Type 2 Diabetes Echo Therapeutics, Inc. (OTC Bulletin Board: ECTE), a company developing its needle-free Symphony(TM) tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and the Prelude(TM) SkinPrep System...
5. European Society Of Cardiology To Give Talks On Diabetes In Three Cities In China As a result of successful events organised last year, a second Joint Scientific Forum, organised by the European Society of Cardiology (ESC) and the European Association for the Study of...
6. KineMed Receives An Investigator-Initiated Study Grant To Further Explore Mechanism(s) Of Action Associated With Welchol® In Type 2 Diabetes Melli KineMed, Inc., a translational and personalized medicine development company, announced today that the company has received an investigator initiated study grant from Daiichi Sankyo, Inc. to conduct a clinical study...
7. European Society Of Cardiology To Give Talks On Diabetes In Three Cities In China As a result of successful events organised last year, a second Joint Scientific Forum, organised by the European Society of Cardiology (ESC) and the European Association for the Study of...
8. Cardiovascular Risk In Youth With Type 1 Diabetes Linked Primarily To Insulin Resistance According to a new study accepted for publication in The Endocrine Society's Journal of Clinical Endocrinology & Metabolism (JCEM), youth with type 1 diabetes have now been found to have...
9. Surgery Recognized As Effective Treatment For Selected Type 2 Diabetes Patients A first-of-its-kind consensus statement by 50 medical experts from around the world has pronounced surgery to be a legitimate and effective treatment for type 2 diabetes, bringing the procedure a...
10. Rapid-Acting Insulin Analogues: Trials Provide No Proof Of Additional Benefit For Children And Adolescents With Type 1 Diabetes Long-term research is lacking - potential harm remains unclear - valid studies are urgently needed for growing and developing children and adolescents Due to a lack of suitable studies, it...
11. Two Thirds Of Brits Do Not Know The Difference Between Type 1 And Type 2 Diabetes New research out today reveals that less than a third of UK residents (30 per cent) know of type 1 diabetes with a further 59 per cent confusing the autoimmune...
12. Shire Submits European Marketing Authorization Application (MAA) For Velaglucerase Alfa For The Treatment Of Type 1 Gaucher Disease Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today announced that it has submitted a MAA to the European Medicines Agency for velaglucerase alfa, the company's enzyme...
13. Natural Remedies for the Treatment of Type 2 Diabetes As  Dr Patrick Higgins of Toronto might tell you, type II diabetes is the more common of the two types of diabetes. With this type, which almost ninety percent of...
14. Theratechnologies Presents Combined Phase 3 Clinical Results At European AIDS Conference Theratechnologies (TSX:TH) announced that results from a pooled analysis from both its Phase 3 clinical trials evaluating tesamorelin for the treatment of excess abdominal fat in HIV-infected patients with lipodystrophy...
15. Novartis Receives Approval In The European Union For Onbrez® Breezhaler®, A New Once-daily Bronchodilator For Patients With COPD Novartis announced that the European Commission (EC) has approved Onbrez Breezhaler (QAB149 or indacaterol) in both 150 mcg and 300 mcg doses as a new once-daily maintenance bronchodilator treatment of...

« Melatrol Can Be A Decisive Remedy For Insomnia Here Are 8 Useful Remedies on How to Get Rid of Yeast Infections »